• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Get in there, KCI

anonymous

Guest
Wherever Medela was a threat and breathing down your neck’s with drop their pants pricing, which granted, was a small footprint only nationally, take note that they let go of their entire negative pressure sales force yesterday. Save for four reps nationwide who will act in a hybrid role feeling out opportunities. Managers basically demoted to glorified remote rep roles, since they have no direct reports and are lucky to still be retained at all. Marketing team gone and cut to one person. Opportunities will be outsourced to MedPro. New EVP in the states really cleaned house. Good luck capturing market share from KCI with this model, Medela. Guess they will keep their focus on breast pumps, where they belong. Get in there KCI and do your thing. Save your business in the few accounts where they were jeopardizing it.